ReviewInternational journal of molecular medicine2026
Recent progress and therapeutic strategies in the treatment of cervical neuroendocrine neoplasms (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine neoplasms (NENs) are a rare type of tumor originating from peptidergic neurons and neuroendocrine cells, which exhibit neuroendocrine differentiation and neuroendocrine marker expression. NENs can occur in any part of the body, with the cervix being the most common organ for their presentation within the female reproductive system. Small‑cell neuroendocrine carcinoma (NEC) is the most common subtype of cervical NENs, followed by large‑cell NEC. Similar to cervical squamous cell carcinoma (SCC), cervical NENs are closely related to human papillomavirus (HPV) infection, with HPV16 and HPV18 representing the most important subtypes. Cervical NENs are prone to early local spread and distant metastasis, with high malignancy and mortality rates. Currently, there are no clinical guidelines for their diagnosis and treatment, and therapy plans focus on multimodal treatment, combining the experience of cervical adenocarcinoma and SCC with small‑cell lung cancer. Platinum chemotherapy, radical surgery and/or radiotherapy are performed according to staging, and some progress has been made in the use of immunotherapy and targeted therapy. The present review discusses the pathogenesis, treatment, prognosis and future development direction of treatments for NENs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.